ImmunoGen Reports European Medicines Agency Acceptance Of Marketing Authorization Application For Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for Mirvetuximab Soravtansine, a treatment for platinum-resistant ovarian cancer.
October 27, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The acceptance of ImmunoGen's Marketing Authorization Application by the EMA could potentially lead to a new revenue stream for the company if the drug is approved.
The acceptance of the Marketing Authorization Application by the EMA is a positive step towards the commercialization of Mirvetuximab Soravtansine in Europe. If approved, this could potentially open up a new revenue stream for ImmunoGen, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100